{
    "nct_id": "NCT04745910",
    "official_title": "Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial",
    "inclusion_criteria": "For inclusion in the study, patients should fulfill the following criteria:\n\n1. Signed informed consent prior to any study specific procedures (patient or caregiver)\n2. Male or female 18 years of age or older\n3. In the investigator's opinion, expected survival of at least 1 month\n4. Deemed stable by the investigator\n5. Serum Uric Acid â‰¥ 6 mg/dL\n6. Risk for tumor lysis syndrome based on the MD Anderson TLS risk score\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Patients will be ineligible for study enrollment if any of the following exclusion criteria are fulfilled:\n\n1. Inability or refusal to give informed consent (patient or caregiver)\n2. Subject unwilling to take study medication\n3. Known allergy to uricase\n4. Pregnant\n5. Breastfeeding\n6. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n7. Transfusion in last 7 days (as this interferes with G6PD test), with the exception of platelet transfusions.\n8. Has received rasburicase during current admission.(Can be considered i24 hours after last Rasburicase administered, current or previous admission)",
    "miscellaneous_criteria": ""
}